Background: Text generation approaches in health care communication have evolved along 2 major paths. The first path involves generative adversarial networks, progressing from basic architectures to specialized variants like Text-to-Text Generative Adversarial Network (TT-GAN) and Time and Frequency Domain-Based Generative Adversarial Network (TF-GAN), which address challenges in discrete text generation through techniques such as Gumbel-Softmax and reinforcement learning. The second path emerges from transformer-based architectures, particularly Generative Pretrained Transformer-2 (GPT-2), which uses extensive pretraining and self-attention mechanisms to generate contextually appropriate text. GPT-2’s transformer architecture enhances persuasive health communication by generating personalized messages using various strategies like task support, dialogue support, and social support for effective health interventions. Objective: This study aimed to use GPT-2 as a generative method to construct persuasive text in a dataset and compare the performance of sentiment analysis and emotion detection analysis. Methods: We combined sentiment analysis tools (VADER [Valence Aware Dictionary and Sentiment Reasoner] and TextBlob) with emotion detection methods (Text2Emotion and NRCLex [National Research Council Lexicon]) to analyze health coaching messages across different persuasive types: reminder, reward, suggestion, and praise. Results: TextBlob and VADER achieved accuracies of 57% and 69%, respectively, while RoBERTa (robustly optimized BERT approach)-sentiment outperformed them with an accuracy of 88%. Emotion detection showed a high prevalence of “joy” and “happy” labels (93.69% positive skew). While transformers excel in accuracy, lexicon-based models like VADER offer a better performance-efficiency balance for real-time health communication systems. For emotion detection, all categories showed perfect accuracy (1.0), while trust showed mixed results, with precision, recall, and -score values ranging from 0.81 to 0.96. The emotion detection analysis revealed varying success rates across different emotions, with some categories, such as anger and neutral, showing reasonable performance and others, such as trust, showing mixed performance. Conclusions: This research contributes to understanding the emotional dynamics of persuasive health communication and highlights both the capabilities and limitations of current natural language processing tools in analyzing health-related persuasive messaging. This proof-of-concept study using synthetically generated data establishes a methodological framework for multimodal sentiment and emotion analysis. The findings require validation with real-world health coaching messages before clinical deployment.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/65f97eec698c3cad7ae43215b3f82aa1" />
Factors Influencing the Use of Mobile Apps and Wearables: Pre- and Post-Surgery Quality of Life Assessment Study
Background: Quality of life (QoL) is an important surgical outcome, commonly assessed through self-reports, and has the potential to be enhanced by objective information from personal technologies such as smartphone apps and wearables. Understanding patients’ perspectives on this application of personal technologies is scarce. Objective: This study aimed to identify operational aspects of smartphone- and wearable-based assessments, as well as human and operational factors that may influence the acceptability of already owned (mostly smartphone) or new (mostly wearable) technologies by patients for pre- and post-surgery QoL assessments. Methods: Through purposive sampling, 41 patients from 3 health care centers in Switzerland, the United States, and the United Kingdom, who were undergoing or scheduled for surgery for degenerative cervical myelopathy (DCM), liver transplantation, or total hip replacement, were interviewed about their perceptions of QoL, current use of smartphones, health apps, and wearables for self-management and their views on using these technologies to assess QoL before and after surgery. Results: Across the 3 studies (n=41), most (n=36) patients reported improved QoL after surgery, mainly due to reduced pain and fatigue and regained autonomy, while a few patients with DCM reported no change (n=2) or worsening (n=1). Patients were generally comfortable using smartphones and tablets, but few (n=4) used them for health management. Wearables were perceived differently across groups: they were well accepted in transplant@US, moderately in hip@UK, and least in myelopathy@CH. Many patients with DCM found wearables “useless,” believing they added little to their self-awareness or recovery and could not replace human clinical judgment. Others expressed concerns about privacy, complexity, notifications, and battery life, while some acknowledged their motivational value when the data were clearly interpreted. Despite varying acceptance levels, most participants said they would consider using such devices if they contributed to research or improved care. Conclusions: Given a mostly negative attitude of patients toward wearables, we discuss the use of smartphone-based automated logging of physical functioning (sleep and physical activity) instead. Such logging may be less accurate than a dedicated wearable, but it may be accurate enough to measure their pre- and post-surgery physical functioning changes. Additionally, a smartphone has the advantage of being already well integrated into the daily life of patients from the perspective of its functionality and the patients’ routines, contrary to wearable devices, which would have been provided to the patients in the context of pre- and post-surgery clinical care and require additional attention for their continuous wear, charging, and data synchronization, among others.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/bcd470214df20bf7565f949b56fb5ae1" />
Alzheimer’s Linked to Cancer Mutations in Brain Immune Cells
As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research reported by researchers at Boston Children’s Hospital suggests that the brain’s resident immune cells, microglia, amass mutations in specific cancer-driving genes, yet they don’t manifest as cancer. Instead, these mutations may help drive Alzheimer’s disease.
The research team, led by Christopher Walsh, MD, PhD, chief of the Division of Genetics and Genomics at Boston Children’s and an investigator of the Howard Hughes Medical Institute, and collaborators Alice Eunjung Lee, PhD, and August Yue Huang, PhD, also in the Division of Genetics and Genomics—who are all professors at Harvard Medical School and associate members of the Broad Institute of MIT and Harvard—say their study findings may provide insights into new Alzheimer’s disease diagnostics and treatments.
“We find that to some extent, Alzheimer’s disease is a little like cancer—driven by the same mutations that drive blood cancers like lymphoma and leukemia,” said Walsh. “This is helpful because we have a lot of drugs to fight cancer and some of them might be useful therapeutically for Alzheimer’s disease.”
The researchers reported on their work in Cell, in a paper titled “Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states.”
Microglia function as the brain’s resident immune cells, acting as garbage collectors, eating debris and infected or dying cells. “The importance of microglia in Alzheimer’s disease (AD) pathogenesis has been demonstrated by large-scale genetic association studies, which have identified AD risk variants in a growing list of microglia-related genes,” the authors wrote. “Once abnormally reactive in AD, microglia can promote synaptic and neuronal loss while exacerbating tau proteinopathy.”
Unlike the rest of the immune system cells that circulate in the blood throughout the body, microglia don’t cross the blood brain barrier—or so experts thought. For their newly reported study the research team sequenced 149 cancer-driving genes from tissue samples in 190 brains donated from people with Alzheimer’s disease compared to 121 healthy brains. The Alzheimer’s samples had more single DNA letter changes than the healthy tissue with the most changes found repeatedly in the same five cancer driver genes, meaning the microglia were amassing mutations in specific genes. “Deep (>1,000×) panel sequencing of 311 brain samples revealed enrichment of somatic single-nucleotide variants (sSNVs) in cancer driver genes in AD brains, especially in genes associated with clonal hematopoiesis (CH),” the team stated.
The cancer gene mutations the researchers discovered in the microglia are commonly found in blood cancers. Because of this, the team tested blood samples from people with Alzheimer’s disease for these same mutations. The team didn’t expect the blood to have these mutations. However, Walsh’s team found the blood cells of the same Alzheimer’s patients carried the same cancer mutations too.
![Microglia-like immune cells with cancer mutations (purple) emerge in the brain. Separately, clumps of proteins, like Tau or amyloid, accumulate in the brain, making the environment hostile. Those microglia cells with mutations get selected for survival and proliferation, creating an inflammatory environment that makes innocent bystander neurons die, contributing to Alzheimer’s disease. [Christopher Walsh and colleagues at Boston Children's Hospital]](https://www.genengnews.com/wp-content/uploads/2026/04/Low-Res_Walsh-Cell-photo-300x300.jpg)
“These sSNVs were associated with clonal expansion and carried by both microglia-like brain macrophages (MLBMs) in multiple brain regions as well as paired blood, suggesting a likely hematopoietic origin,” the investigators stated. “It was actually a really unexpected finding that suggests a totally new mechanism for Alzheimer’s disease pathogenesis,” said Huang. “The findings mean that the blood’s immune cells with cancer mutations are likely getting into the brain and contributing to disease.”
The researchers theorize that the blood-brain barrier weakens, either by age or injury, allowing the blood’s immune cells to cross into the brain. These new arrivals then convert into microglia-like cells. Separately, clumps of proteins accumulate in the brain, triggering microglia to proliferate and respond. The cells most likely to dominate are those with a selective advantage, such as the microglia-like cells with the cancer mutations. However, these mutant microglia also make the environment more inflammatory and hostile than that of the healthy microglia, causing innocent bystander neurons to die off, which leads to Alzheimer’s disease. “These findings suggest that clonal somatic driver variants in MLBMs are enriched in AD, potentially promoting neuroinflammation and neurodegeneration,” the researchers noted. “Potential roles of somatic cancer driver variants in AD pathogenesis open up a whole new range of therapeutic avenues in AD, complementary to approaches emphasizing amyloid and tau.”
Lee added, “Because it’s hard to access brain tissue in a living patient, genetic screens using blood samples could be developed to test whether a person carries these mutations, and has an increased risk of developing Alzheimer’s disease.” Lee and Huang performed a follow-up study, now posted as a preprint on bioRxiv. Here, they demonstrated that cancer driver mutations observed in patient blood samples increased risk of Alzheimer’s disease independently of a well-established genetic risk factor, APOE4.
The post Alzheimer’s Linked to Cancer Mutations in Brain Immune Cells appeared first on GEN – Genetic Engineering and Biotechnology News.
AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model
SAN DIEGO – A new AI model applied to routine pathology slides accurately predicts outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). The study was study presented at the American Association for Cancer Research (AACR) Annual Meeting.
“Immunotherapy has transformed cancer treatment, but only a subset of patients benefit from it, and predicting who will respond remains challenging,” said Rukhmini Bandyopadhyay, PhD, a postdoctoral fellow at The University of Texas (UT) MD Anderson Cancer Center.
“This study represents, to our knowledge, the first deep learning-based pathomics biomarker rigorously validated across international real-world cohorts and a Phase III randomized clinical trial, directly addressing one of the most urgent unmet needs in precision oncology: reliable patient selection and stratification for immunotherapy,” he continued.
Pathomics applies computational and machine learning methods for high-throughput analysis of digital pathology images to extract large-scale data related to cell and tissue architecture linked to disease outcomes.
Bandyopadhyay and colleagues developed a deep learning survival prediction model called Pathology-driven Immunotherapy Optimization (Path-IO), which can study patterns across tissue to identify patients most likely to benefit from immunotherapy. The model then combines imaging and clinical data to estimate whether a patient may have a higher or lower risk of poor outcomes from immunotherapy.
The researchers tested the platform in a study that included 797 immune checkpoint inhibitor-treated NSCLC patients from UT MD Anderson, with external validation in 280 additional patients from Mayo Clinic, Gustave Roussy, and the Phase III Lung-MAP S1400I trial in which immunotherapy-naïve patients with lung squamous cell carcinoma, a subtype of NSCLC, were treated with immune checkpoint inhibitors.
The model reliably stratified patients into higher and lower risk groups. In the UT MD Anderson cohort, patients in the high‑risk group had more than double the risk of death or disease progression compared with patients in the low‑risk group.
Model performance was evaluated using the concordance index (C-index), which measures how well each biomarker distinguishes between patients with different outcomes. Notably, Path-IO consistently outperformed PD-L1, the U.S. Food and Drug Administration-validated standard-of-care biomarker for guiding immunotherapy use in NSCLC patients, across both discovery and test cohorts.
PD-L1 alone showed limited prognostic performance, with C-indices of 0.58 for overall survival (OS) and 0.57 for progression-free survival (PFS) in the discovery cohort, declining to 0.50 and 0.51, respectively, in the test cohort. In contrast, Path-IO demonstrated stronger discriminative ability, achieving C-indices of 0.69 for OS and 0.65 for PFS in the discovery cohort and 0.63 for OS and 0.58 for PFS in the test cohort.
Combining pathology-based predictions with radiomics and clinical data further improved the model’s performance, with the C-index increasing from 0.58 to 0.70 for PFS and from 0.63 to 0.75 for OS.
Given that the approach was designed to be applied to routine pathology slides, the platform can be incorporated into existing clinical workflows without significant expense compared to other emerging data-based technologies.
As the study is retrospective, further investigation is needed to go beyond the identification of patients who would benefit from immunotherapy and help predict what type of immunotherapy they can benefit from. Future directions include prospective validation and the integration of paired, more comprehensive molecular profiling to enhance predictive performance.
The post AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model appeared first on GEN – Genetic Engineering and Biotechnology News.
Cosmo Pharma Eyes 2027 NDA for Baldness Candidate After Positive Phase III 12-Month Data
Cosmo Pharmaceuticals says it plans to file for FDA approval of its androgenetic alopecia (AGA) candidate clascoterone 5% topical solution early next year, after the androgen receptor inhibitor generated 12-month Phase III data showing statistically significant continued hair growth as well as positive safety for chronic use.
Data from Cosmo’s Phase III program for clascoterone confirmed the drug’s long-term safety profile was comparable to vehicle, supporting suitability for chronic use in a lifelong condition. Clascoterone also showed a novel mechanism designed to target the underlying biology of hair loss and continued efficacy with ongoing use, Cosmo said.
A total of 1,465 patients were enrolled in the Phase III program, the largest for any topical treatment candidate for male AGA, according to Cosmo. The program consists of the SCALP 1 (NCT05910450) and SCALP 2 (NCT05914805) trials, which evaluated patients across 51 study centers in the United States and Europe.
Patients who remained on continuous clascoterone treatment for the full 12 months achieved a statistically significant 239% improvement in Target Area Hair Count (TAHC) compared with patients who received clascoterone for six months and were then switched to vehicle from month 7 to month 12, according to Cosmo.
That’s down slightly from the 252% improvement in TAHC shown for clascoterone versus “vehicle” or placebo in Cosmo’s six-month results, released in December. Cosmo Pharma CEO Giovanni Di Napoli told GEN that the 6- and 12-month results were not directly comparable due to differences in Part 1 and Part 2 of the Phase III placebo-controlled program and the corresponding patient groups being compared.
Part 1 is a double-blind study assessing if clascoterone was effective and safe compared to placebo when applied twice daily for up to six months. Part 2 is a single blind study that measured clascoterone’s long-term safety and efficacy versus placebo for an additional six months in patients who had responded to the study drug in Part 1. During Part 2, participants were re-randomized to receive either clascoterone 5% solution or vehicle solution.
SCALP 1 enrolled 702 patients in the United States, while SCALP 2 enrolled 763 patients in the Unites States as well as Germany and Poland.
Primary outcome measures
Change in vellus TAHC (hair of up to 30 micrometers in diameter) from baseline was the trials’ primary outcome measure, paired with a patient-reported outcome assessing participants’ perception of hair growth improvement.
Additional assessments of the trials included investigator-reviewed global scalp photography and secondary endpoints that included changes in non-vellus TAHC (thicker, pigmented hair >30-40 micrometers in diameter), and changes in subject’s assessment of satisfaction score.
Patients treated with clascoterone for 12 months reported a statistically significant +24.5% relative improvement in treatment satisfaction versus vehicle groups, according to Cosmo. The clascoterone users also reported positive ease of use and product acceptability at month 12—results that according to the company support positive real-world usability and long-term adherence potential for the drug.
Cosmo said it plans to submit its full Phase III dataset for publication in a leading peer-reviewed medical journal and present its findings at future major dermatology congresses.
‘Defining moment’
“These 12-month Phase III results mark a defining moment for clascoterone and for the treatment of male hair loss,” Di Napoli stated. “We are now seeing the combination that matters most: positive long-term safety, statistically significant continued hair growth through one year, and clear evidence that ongoing treatment drives sustained benefit.”
Investors responded to the positive 12-month data by sending Cosmo shares traded on the SIX Swiss Exchange rising 6% on the day of the announcement, from CHF95.50 ($122.69) to CHF101.40 ($130.27) on April 15. Since then shares have fluctuated in the high CHF 90 range, closing Monday at CHF 98.50 ($126.55).
Di Napoli said clascoterone has the potential to emerge as a major new therapeutic option and a highly valuable growth platform for Cosmo by tackling the most common cause of hair loss in men. Androgenetic alopecia, also called male pattern hair loss, affects approximately 40% of men worldwide—including 39% of males in the United States (65 million men).
“We are moving with urgency toward regulatory submissions and commercialization discussions,” Di Napoli added.
Cosmo’s results “likely now enable more advanced partnership discussions, in our view, with detailed presentation of results the next step to fully de-risk the asset,” Benjamin Jackson, equity analyst with Jefferies, wrote April 15 in a research note.
Jackson predicted clascoterone could generate $4 billion in peak-year worldwide sales.
“Our $4 billion WW potential peak sales require just 4% penetration of treated and 6% penetration of untreated men at peak, assuming a capable commercial partner is successfully found,” Jackson added.
Cosmo said it is preparing to submit not only an NDA for clascoterone in the U.S., but a marketing authorization application to the European Medicines Agency.
Clascoterone’s 1% formulation is already FDA-approved and marketed as Winlevi® for topical treatment of acne vulgaris in patients ages 12 and older.
The post Cosmo Pharma Eyes 2027 NDA for Baldness Candidate After Positive Phase III 12-Month Data appeared first on GEN – Genetic Engineering and Biotechnology News.
GABA-Based Target for Alzheimer’s Therapy Identified
Researchers at the University of Galway have found evidence that targeting inhibitory signaling in the brain may help address cognitive dysfunction in Alzheimer’s disease (AD), a finding that runs counter to current therapeutic approaches that focus on influencing excitatory pathways. The research, published in Neuropharmacology, identifies how modulation of gamma-aminobutyric acid (GABA) signaling can restore disrupted neural balance and improve memory-related function in AD disease models.
“Given the ever-increasing burden of Alzheimer’s disease, the urgent need for the identification of novel targets for the development of disease-modifying therapy is clear,” said senior author Andrea Kwakowsky, PhD, associate professor of pharmacology and lead researcher at the School of Medicine, University of Galway.
Alzheimer’s disease is characterized by progressive cognitive impairment and is associated with hallmark pathological features including β-amyloid (Aβ) plaques and neurofibrillary tangles. In addition to these, disruption of the brain’s excitatory/inhibitory (E/I) balance has gained traction as a central mechanism contributing to memory loss. Today, most approved therapies for AD target excitatory neurotransmitter systems such as cholinergic and glutamatergic pathways, but “the symptomatic relief provided by these therapies is only marginal, and the progression or underlying causes of the disease are not addressed,” the researchers noted.
For their work, the University of Galway team instead focused on the inhibitory side of this balance, specifically the role of gamma-aminobutyric acid (GABA), the brain’s main inhibitory neurotransmitter. GABA regulates neuronal activity and is essential for maintaining stable network function and memory processes. In AD, however, E/I balance becomes dysregulated with increased extracellular GABA—triggered in part by Aβ—leading to overactivation of certain GABA receptors, particularly α5-containing GABA type A receptors (α5-GABA ARs), which are abundant in the hippocampus. The result is a dampening of neuronal signaling and which impairs learning and memory.
“Our research is significant in that it demonstrates that if we block this GABA receptor activity in nerve cells we can reverse Alzheimer-like effects caused by amyloid beta and improve cognitive performance,” Kwakowsky said.
To test whether blocking a5-GGABA A could help restore E/I balance, the team investigated α5IA, an α5-GABA AR-selective inverse agonist. α5IA works by reducing the activity of α5-GABA ARs, which decreases excess tonic inhibition. The data showed that in experimental models of AD, the compound improved long-term potentiation (LTP), a mechanism of synaptic plasticity and memory, reduced abnormal inhibitory conductance, and restored spatial memory performance.
Mechanistically, α5IA appears to act by restoring physiological levels of inhibition in the hippocampus which is critical for memory formation. By reducing excessive tonic inhibition, it rebalances E/I signaling, which allows neuronal circuits to function more effectively. “The data presented here suggest that in both ex vivo and in vivo AD models, α5IA improves cognitive function by restoring CA1 tonic inhibition, thereby re-establishing E/I balance and ameliorating the abnormal hippocampal network activity induced by Aβ1-42,” the researchers wrote.
This new study is the latest to indicate that targeting inhibitory neurotransmission could be an effective treatment approach for AD. Earlier research has shown that α5-GABA AR modulation enhances memory and reduces inhibitory signaling in both animal models and humans. But most of these studies have not directly examined the effect of α5IA in chronic neurodegenerative disease models.
The researchers noted there are some limitations to their work, pointing out that while α5IA improved cognitive outcomes, it did not reverse neuronal loss in vivo, suggesting that its effects may be primarily functional rather than neuroprotective at later stages of AD. Also, variability in drug exposure and timing may influence outcomes. Finally long-term use of α5IA has also been associated with safety concerns at high doses, including renal toxicity, so further research is needed to determine toxicity and dosing regimens and limits.
Nonetheless, the implications of this research indicate there is potential to develop new AD therapies that directly target network dysfunction rather than focusing solely on amyloid accumulation or excitatory signaling. By restoring E/I balance, this approach shows the potential to improve cognitive function even when AD pathology has taken root. The findings could also benefit diagnostic methods, as biomarkers of inhibitory dysfunction or altered GABA signaling could help identify patients who would benefit an approach that rebalances E/I signaling.
The post GABA-Based Target for Alzheimer’s Therapy Identified appeared first on Inside Precision Medicine.
Sepsis Fast Diagnostics Could Save Lives and Billions in Costs
Fast diagnostics could improves patient outcomes and save billions in healthcare costs if used systematically to identify sepsis in hospitalized adults at risk due to bloodstream infections, according to an independent report.
The research encompassing all G7 countries revealed multiple benefits from earlier intervention for time-critical infections through the extensive application of fast identification and antimicrobial susceptibility testing (Fast ID/AST).
The Value of Fast Diagnostics in Time-critical Infections report by the independent Office of Health Economics showed how systematic use of fast diagnostics would lead to far fewer sepsis-related deaths and significantly decrease long-term post-sepsis complications, thereby improving patients’ quality of life.
The multi-country economic evaluation, commissioned and funded by bioMérieux, also showed major savings in healthcare costs each year, with the magnitude dependent on country size, incidence, and cost structures.
“While the magnitude varies by country, the direction is consistent: the model demonstrates that early diagnostics reduce the likelihood that high-risk patients progress to sepsis,” said Julien Textoris, PhD, vice president of EMEA medical affairs at bioMérieux.
“Preventing cases of sepsis could therefore reduce the risk of long-term complications after hospital discharge, including recurrent infections, cognitive decline, psychological effects, and organ-specific complications.”
Sepsis is a life-threatening reaction to an infection responsible for 21 million deaths worldwide each year. The initial hours of management are crucial, with targeted antibiotic treatment a key predictor of survival.
However, conventional methods for diagnosis takes at least a couple of days deliver results and nearly one in five bloodstream infection patients receive an inappropriate initial treatment.
In a model-based health economic analysis, Shaheer Hassan and co-workers at the OHE examined what would happen if fast ID/AST were systematically used early in the care pathway before clinical deterioration occurs.
The study encompassed Canada, France, Germany, Italy, Japan, the United Kingdom, and the U.S. and used expert-validated clinical inputs, country-specific cost data, and conservative assumptions.
Results revealed consistent cost savings regardless of the structure or financing of the healthcare system.
More than half of all savings—between 53% and 83%—would occur during the initial hospitalization, when the clinical and economic consequences of deterioration are most evident.
This is because early diagnostic information would prevent the chances of patients progressing into one of the most resource intensive stages of sepsis care.
The savings per patient ranged from €500 in Canada to €3,800 in Japan. This was primarily driven by fewer admissions to the intensive care unit, shorter hospital stays, and educed management of severe complications.
Annual national savings ranged from €26 million in Canada to €2.5 billion in the U.S. and reflected both cost savings in the acute phase and from reduced long-term complications.
“To realize these benefits, hospitals must address structural and workflow barriers so fast results translate into faster therapy, alongside broader system reforms to correct the persistent undervaluation of diagnostics,” the report maintained.
“Overcoming the underutilization and undervaluation of diagnostics will require coordinated system-level action, with the G7 countries included in this analysis well-positioned to lead.”
The post Sepsis Fast Diagnostics Could Save Lives and Billions in Costs appeared first on Inside Precision Medicine.
<![CDATA[Emerging student researchers share their award-winning neuroscience and psychiatry projects.]]>
Changes in Internet Search Term Popularity in Elder Mistreatment (2018-2023): Infodemiology Study of Google Trends Data
Background: Elder mistreatment (EM) is a significant public health problem that is frequently underdetected and underreported. Insufficient public recognition and engagement have been hypothesized as one contributor to this underreporting; however, few data sources exist to quantify public awareness or engagement with EM at the population level. Objective: This study examined relative internet search interest in EM compared with other forms of abuse (child abuse and domestic violence) in the United States using Google Trends data. Methods: We analyzed Google Trends data to compare the Relative Search Index (RSI) for the terms “elder abuse,” “child abuse,” and “domestic violence” in the United States from December 2018 to December 2023. RSI values reflect normalized search activity relative to the maximum search volume within the specified period. Results: Mean RSI values for “elder abuse” were substantially lower than those for “child abuse” (11.35 vs 50.21) and “domestic violence” (6.96 vs 63.50). Ad hoc tests for stationarity indicated that RSI values for all 3 terms remained stable over the 5-year study period. During Elder Abuse Awareness Month, RSI for “elder abuse” increased relative to “child abuse” and “domestic violence” by 8.3 and 5.7 points, respectively, compared with other months of the year. Conclusions: Relative search interest in elder abuse appears to be persistently lower than that for child abuse and domestic violence, despite modest increases during Elder Abuse Awareness Month. Although Google Trends does not provide a validated measure of public awareness, search-based metrics such as RSI may offer a scalable, low-cost complement to traditional data sources for contextualizing public engagement with EM and informing future awareness, detection, and prevention efforts.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/c61b6ae514b9fbbb46e3ceb6ec8ca2e5" />
Navigating with Excellence: The Multi-Faceted Service Lines of Precision Logistics
The global pharmaceutical industry operates within one of the most demanding and high-stakes environments of our modern world. Unlike traditional retail supply chains, pharmaceutical logistics is a discipline defined by extreme sensitivity, rigorous regulatory oversight, and an unwavering commitment to patient and product safety. It is the pinnacle of expertise on what happens insideand outside a shipment during its journey.
Marken UPS Healthcare Precision Logistics doesn’t simply move packages. We manage a complexecosystem of specialized service lines designed to maintain the integrity of priority shipping and lifesaving medications from the point of manufacture to the patient’s bedside. Understanding these services is essential for an appreciation of how modern medicine reaches the global population with its efficacy intact.
Specialty logistics distinguishes itself from general freight through a relentless commitment to technical precision and customized infrastructure. While standard shipping relies on high-volume throughout and routine packaging, specialty logistics demands a bespoke approach to every mile of the journey. This often involves the integration of advanced cold chain innovation to maintain biological integrity or the deployment of specialized technology for visibility of critical materials and equipment in transit.
Beyond the physical hardware, the sector is defined by a rigorous regulatory landscape where practitioners must navigate a complex web of international compliance, hazardous material protocols, and detailed chain-of-custody requirements. In this environment, good enough is never an option. Every variable, from the precise humidity levels of a storage facility to vibration dampening on a pallet shipper, is carefully monitored.
This level of granularity ensures that whether a shipment contains a life-saving pharmaceutical batch or a one-of-a-kind special piece of equipment, it arrives not just on time, but in its exact intended state. Consequently, precision logistics serve as the invisible backbone for industries where the cost of failure far exceeds the cost of transport, necessitating a fusion of engineering, legal expertise, and sophisticated data analytics to manage the inherent risks of moving the world’s most challenging cargo.
Transitioning from the theoretical complexities of the industry to the practical execution of a global supply chain requires an adaptable, expert-led approach. While the challenges of specialized logistics are diverse, ranging from strict thermal requirements to extreme environmental demands, Marken’s operational framework is built on seven distinct pillars of excellence.
Each of these service lines has been engineered to address a specific facet of the logistical puzzle, providing the specialized equipment, certified personnel, and rigorous oversight necessary to mitigate risk. By categorizing our capabilities into these dedicated sectors, we ensure every project receives a novel strategy rather than a one-sizefits- all solution.
These service lines represent more than just transportation or clinical trial categories. They are specialized disciplines derived from decades of work in logistics that allow us to maintain a high rate of success for the world’s most sensitive and high-value cargo. In this eBook, Marken experts share how these precision-driven services ensure the performance, reliability, and success of global supply chains.
The post Navigating with Excellence: The Multi-Faceted Service Lines of Precision Logistics appeared first on GEN – Genetic Engineering and Biotechnology News.